Literature DB >> 29487110

Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.

Cen Guo1, Carl LaCerte1, Jeffrey E Edwards1, Kenneth R Brouwer1, Kim L R Brouwer2.   

Abstract

The farnesoid X receptor (FXR) is a nuclear receptor that regulates genes involved in bile acid homeostasis. FXR agonists, obeticholic acid (OCA) and chenodeoxycholic acid (CDCA), increase mRNA expression of efflux transporters in sandwich-cultured human hepatocytes (SCHH). This study evaluated the effects of OCA and CDCA treatment on the uptake, basolateral efflux, and biliary excretion of a model bile acid, taurocholate (TCA), in SCHH. In addition, changes in the protein expression of TCA uptake and efflux transporters were investigated. SCHH were treated with 1 µM OCA, 100 µM CDCA, or vehicle control for 72 hours followed by quantification of deuterated TCA uptake and efflux over time in Ca2+-containing and Ca2+-free conditions (n = 3 donors). A mechanistic pharmacokinetic model was fit to the TCA mass-time data to obtain estimates for total uptake clearance (CLUptake), total intrinsic basolateral efflux clearance (CLint,BL), and total intrinsic biliary clearance (CLint,Bile). Modeling results revealed that FXR agonists significantly increased CLint,BL by >6-fold and significantly increased CLint,Bile by 2-fold, with minimal effect on CLUptake Immunoblotting showed that protein levels of the basolateral transporter subunits organic solute transporter α and β (OSTα and OSTβ) in FXR agonist-treated SCHH were significantly induced by >2.5- and 10-fold, respectively. FXR agonist-mediated changes in the expression of other TCA transporters in SCHH were modest. In conclusion, this is the first report demonstrating that OCA and CDCA increased TCA efflux in SCHH, which contributed to reduced intracellular TCA concentrations. Increased basolateral efflux of TCA was consistent with increased OSTα/β protein expression in OCA- and CDCA-treated SCHH.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29487110      PMCID: PMC5893928          DOI: 10.1124/jpet.117.246033

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  59 in total

1.  The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp.

Authors:  L A Denson; E Sturm; W Echevarria; T L Zimmerman; M Makishima; D J Mangelsdorf; S J Karpen
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

2.  Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression.

Authors:  Wensheng Chen; Shi-Ying Cai; Shuhua Xu; Lee A Denson; Carol J Soroka; James L Boyer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-02-01       Impact factor: 4.052

3.  Hepatobiliary transport kinetics of the conjugated bile acid tracer 11C-CSar quantified in healthy humans and patients by positron emission tomography.

Authors:  Nikolaj Worm Ørntoft; Ole Lajord Munk; Kim Frisch; Peter Ott; Susanne Keiding; Michael Sørensen
Journal:  J Hepatol       Date:  2017-02-27       Impact factor: 25.083

4.  Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.

Authors:  Maria Rius; Johanna Hummel-Eisenbeiss; Alan F Hofmann; Dietrich Keppler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-11-10       Impact factor: 4.052

5.  The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.

Authors:  Jean-François Landrier; Jyrki J Eloranta; Stephan R Vavricka; Gerd A Kullak-Ublick
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-11-03       Impact factor: 4.052

6.  Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities.

Authors:  Sumio Ohtsuki; Olaf Schaefer; Hirotaka Kawakami; Tae Inoue; Stephanie Liehner; Asami Saito; Naoki Ishiguro; Wataru Kishimoto; Eva Ludwig-Schwellinger; Thomas Ebner; Tetsuya Terasaki
Journal:  Drug Metab Dispos       Date:  2011-10-12       Impact factor: 3.922

Review 7.  Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.

Authors:  Luciano Adorini; Mark Pruzanski; David Shapiro
Journal:  Drug Discov Today       Date:  2012-05-29       Impact factor: 7.851

8.  Induction of ABCC3 (MRP3) by pregnane X receptor activators.

Authors:  Shirley Teng; Veronika Jekerle; Micheline Piquette-Miller
Journal:  Drug Metab Dispos       Date:  2003-11       Impact factor: 3.922

9.  Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.

Authors:  Gernot Zollner; Peter Fickert; Dagmar Silbert; Andrea Fuchsbichler; Hanns Ulrich Marschall; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  J Hepatol       Date:  2003-06       Impact factor: 25.083

Review 10.  Obeticholic acid for the treatment of primary biliary cirrhosis.

Authors:  Palak J Trivedi; Gideon M Hirschfield; M Eric Gershwin
Journal:  Expert Rev Clin Pharmacol       Date:  2015-11-07       Impact factor: 5.045

View more
  13 in total

Review 1.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

2.  Probe Cocktail to Assess Transporter Function in Sandwich-Cultured Human Hepatocytes.

Authors:  Cen Guo; Kenneth R Brouwer; Paul W Stewart; Caroline Mosley; Kim L R Brouwer
Journal:  J Pharm Pharm Sci       Date:  2019       Impact factor: 2.327

Review 3.  Farnesoid X receptor: a potential therapeutic target in multiple organs.

Authors:  Chao Zhang; Zixuan Wang; Qingqing Feng; Wei-Dong Chen; Yan-Dong Wang
Journal:  Histol Histopathol       Date:  2021-01-04       Impact factor: 2.303

4.  Identification of Key Amino Acids that Impact Organic Solute Transporter α/β (OSTα/β).

Authors:  William A Murphy; James J Beaudoin; Tuomo Laitinen; Noora Sjöstedt; Melina M Malinen; Henry Ho; Peter W Swaan; Paavo Honkakoski; Kim L R Brouwer
Journal:  Mol Pharmacol       Date:  2021-10-01       Impact factor: 4.054

5.  Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications.

Authors:  Izna Ali; Seher Khalid; Bruno Stieger; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2019-01-25       Impact factor: 4.939

6.  Role of Organic Solute Transporter Alpha/Beta in Hepatotoxic Bile Acid Transport and Drug Interactions.

Authors:  James J Beaudoin; Jacqueline Bezençon; Noora Sjöstedt; John K Fallon; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

7.  Novel in Vitro Method Reveals Drugs That Inhibit Organic Solute Transporter Alpha/Beta (OSTα/β).

Authors:  Melina M Malinen; Antti Kauttonen; James J Beaudoin; Noora Sjöstedt; Paavo Honkakoski; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2018-12-14       Impact factor: 4.939

Review 8.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

Review 9.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 10.  Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.

Authors:  Virender Kumar; Xiaofei Xin; Jingyi Ma; Chalet Tan; Natalia Osna; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2021-07-24       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.